Literature DB >> 9524961

Action of pituitary and lymphocyte prolactin.

L Matera1.   

Abstract

In vivo and in vitro data combined show that prolactin (PRL) can mimic or interact with known lymphocyte cytokines and that these, in turn, can regulate PRL synthesis at the site of immune response. In contrast, pituitary PRL is under the control of both immune system products (non-cognitive stimuli) and signals to the CNS (cognitive stimuli). The role of PRL as a cytokine and as an endocrine hormone is discussed. In particular, assignment of PRL to the T helper 1 phenotype is proposed, based on its ability to enhance NK cell function, activate the interferon-regulated factor (IRF-1) transcription factor and to interact with or generate IL-2 and IFN gamma. Since hyperprolactinemia and hypoprolactinemia are both immunosuppressive, physiological levels of circulating PRL must be necessary to maintain normal immunocompetence. Moderate increases in PRL during immune stimulation of the hypothalamic-pituitary axis may counteract glucocorticoid inhibition, whereas inappropriate prolongation of PRL synthesis could lead to autoimmune diseases. Increased release of PRL by the pituitary during stress may inhibit NK cell antitumor cytotoxicity. The variety of PRL isotypes, the existence of multiple receptor subunits, and the complexity of their intracellular signaling may explain the specificity of PRL action on different target cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9524961     DOI: 10.1159/000097335

Source DB:  PubMed          Journal:  Neuroimmunomodulation        ISSN: 1021-7401            Impact factor:   2.492


  9 in total

Review 1.  Extrapituitary production of anterior pituitary hormones: an overview.

Authors:  S Harvey; C Arámburo; E J Sanders
Journal:  Endocrine       Date:  2011-11-15       Impact factor: 3.633

Review 2.  Prolactin and autoimmunity.

Authors:  Annamaria De Bellis; Antonio Bizzarro; Rosario Pivonello; Gaetano Lombardi; Antonio Bellastella
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

3.  Serum Prolactin Levels in Multiple Sclerosis, Neuromyelitis Optica, and Clinically Isolated Syndrome Patients.

Authors:  Recai Türkoğlu; Murat Giriş; Mehmet Gencer; Uğur Akcan; Arda Örçen
Journal:  Noro Psikiyatr Ars       Date:  2016-12-01       Impact factor: 1.339

Review 4.  Prolactin: The Third Hormone in Breast Cancer.

Authors:  Linda A Schuler; Kathleen A O'Leary
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-16       Impact factor: 6.055

Review 5.  Pathogenesis of systemic lupus erythematosus.

Authors:  C C Mok; C S Lau
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

6.  Effect of prolactin on carcinoembryonic antigen-specific cytotoxic T lymphocyte response induced by dendritic cells.

Authors:  L Matera; E Beltramo; E Martinuzzi; S Buttiglieri
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

7.  The PRL -1149 G/T polymorphism and rheumatoid arthritis susceptibility.

Authors:  Yvonne C Lee; Soumya Raychaudhuri; Jing Cui; Immaculata De Vivo; Bo Ding; Lars Alfredsson; Leonid Padyukov; Karen H Costenbader; Mark Seielstad; Robert R Graham; Lars Klareskog; Peter K Gregersen; Robert M Plenge; Elizabeth W Karlson
Journal:  Arthritis Rheum       Date:  2009-05

Review 8.  Role of dopamine in malignant tumor growth.

Authors:  S Basu; P S Dasgupta
Journal:  Endocrine       Date:  2000-06       Impact factor: 3.925

9.  Antiprolactin autoantibodies are associated with hyperprolactinemic status in men infected with human immunodeficiency virus.

Authors:  Alfredo Leaños-Miranda; Iris Contreras-Hernández
Journal:  Endocrine       Date:  2002-11       Impact factor: 3.925

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.